-News release

Joint research with the global seafood producer Maruha Nichiro aiming for the fastest commercialization of cultured fish meat

IntegriCulture Inc. (Head Office: Bunkyo-ku, Tokyo; Representative Director: Yuki Hanyu; hereinafter referred to as “IntegriCulture”) and Maruha Nichiro Corporation (Head Office: Koto-ku, Tokyo; Representative Director, President & CEO: Masaru Ikemi; hereinafter referred to as “Maruha Nichiro”) have commenced joint research on cultured fish meat. IntegriCulture has developed the CulNet System™, which is a low-cost cell culture technology, in addition to food grade culture media. Both of these have been validated for use with bovine and poultry cells. This joint research will expand into using fish cells, with the goal of achieving the world’s fastest commercialization of cultured fish meat.

■ About Maruha Nichiro
Maruha Nichiro has contributed to the food and health of people by supplying good quality fish proteins. This is based on its mission to “be an essential part of society by improving everyone’s daily life with wholesome, safe and healthy food.” In addition, it is working to resolve social issues through its business activities in order to preserve fishery resources and protect the global environment.
In response to the growing global demand for fish, this joint research is being conducted in order to provide sustainable fish proteins while minimizing environmental risks.

■ About IntegriCulture
We developed the low-cost cell culture technology CulNet System™, to be used as a new platform for the biotech field and to expand it to encompass a broad range of others too—like foods and leather made from animal cells.
The system is a patented, versatile cell culture platform technology that mimics the environment of inter-organ interactions in animals. In theory, it can be used to culture all animal cells on a large scale and at low cost. Along with cell-cultured meat, it has a wide variety of other applications. On a laboratory scale, we have already succeeded in producing serum components. Up until now, these have always been very expensive to make, therefore producing them with cultured cells has slashed the cost of cell culture by eliminating the need for costly fetal bovine serum and growth factors.